Lymphocyte-sparing radiotherapy for esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates a novel approach to treating esophageal squamous cell carcinoma (ESCC) by utilizing lymphocyte-sparing radiotherapy, which aims to minimize the depletion of immune cells during treatment. The research focuses on patients with locally advanced ESCC who are undergoing neoadjuvant treatment. By comparing the effects of lymphocyte-sparing radiotherapy to conventional radiotherapy, the study seeks to provide evidence on the potential benefits of preserving lymphocyte levels for improved patient outcomes. The goal is to enhance survival rates and reduce the risk of recurrence or metastasis in affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients are able to understand and are willing to participate in the trial, and a signed consent form can be obtained;
2. Pathologically confirmed esophageal squamous cell carcinoma;
3. locally advanced ESCC (cT3-4 or N+);
4. the age of patients should be more than 18 years, and less than 80 years;
5. aged between 18 and 80 years;
6. KPS score of patients should be more than 80

Exclusion Criteria:

1. diagnosis of metastatic esophageal cancer;
2. Patient refuses to receive systemic drug treatment;
3. clinical diagnosis of pleural metastasis or malignant pleural effusion;
4. Pregnant or breastfeeding women;
5. Severe non-cancerous medical comorbidities that affect the implementation of radiotherapy.

Where it's running

• Ruijin hospital, Shanghai jiaotong university school of medicine
  Shanghai, China, China Recruiting

Study contacts

• Study coordinator: Wei-Xiang Qi, Dr.
• Email: qwx12055@rjh.com.cn
• Phone: +8602164370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating XB010 for patients with solid tumors

  This study is testing a new drug called XB010, alone and with another medication, to see if it can help people with advanced solid tumors who have few other treatment options.

  Recruiting at 18 sites Phase 1 Exelixis · Irvine, California and 19 other locations · NCT06545331

• MR-guided radiotherapy dose escalation for esophageal squamous cell carcinoma

  This trial will try higher, MRI-guided radiation doses together with standard chemotherapy for adults with resectable, locally advanced esophageal squamous cell carcinoma to see if it improves tumor control before surgery.

  Recruiting Phase 1 UMC Utrecht · Utrecht, Utrecht · NCT07359417

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• Radiotherapy target-volume choices in locally advanced esophageal cancer during immunotherapy

  This observational study looks at how doctors outline the radiation area for locally advanced esophageal squamous cell cancer patients treated with radiotherapy and immunotherapy to see which approaches correlate with better outcomes.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07858630

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

• Neoadjuvant therapy with adebrelimab, famitinib, and chemotherapy for resectable ESCC

  This study tests a combination of adebrelimab, famitinib, and chemotherapy before surgery in people with resectable locally advanced esophageal squamous cell carcinoma to see if it can lead to a complete tumor disappearance at the time of surgery.

  Recruiting Phase 2 First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shannxi · NCT07796113

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.